LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Toon Van Gorp(Universitair Ziekenhuis Leuven), Lukáš Rob(Charles University), Weiguo Lü(Women's Hospital, School of Medicine, Zhejiang University), Floor Backes(Gynecologic Oncology Group), Fırat Ortaç(Ankara University), K. Hasegawa(Saitama Medical University), Sakari Hietanen(Turku University Hospital), A. Savarese(Tumori Foundation), Annouschka Laenen(Statistics Belgium), Y.M. Kim(Asan Medical Center), Lisa M. Bodnar(Australia New Zealand Gynaecological Oncology Group), M.P. Barretina Ginesta(Universitat de Girona), L. Gilbert(McGill University Health Centre), Bhavana Pothuri(Gynecologic Oncology Group), Xiaojun Chen(Obstetrics and Gynecology Hospital of Fudan University), Jasmine Lichfield(MSD K.K. (Japan)), Wenxian Wang(Shanghai Medical Information Center), Robert Orlowski(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alain Lortholary(Hôpital privé du Confluent), Brian M. Slomovitz(Mount Sinai Medical Center)
Cited by 2Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis